Abstract Preterm neonates are at risk to acquire infections. In addition to the high mortality associated with sepsis, these patients are at risk for long-term disabilities, particularly neurodevelopment impairment. Several interventions have been evaluated to reduce rates of infections in neonates but have not proven efficacy. Lactoferrin (LF), a milk glycoprotein with anti-inflammatory, immunomodulatory and antimicrobial properties, has the potential to prevent infections in young children. We performed a review of current and ongoing clinical trials of LF for prevention of neonatal sepsis, and found eleven registered clinical trials that include more than 6,000 subjects. Few of these trials have finished; despite their small sample size, the preliminary results show a trend towards a positive protective effect of LF on neonatal infections. Larger trials are underway to confirm the findings of these initial studies. This information will help to define LF's role in clinical settings and, if proven effective, would profoundly affect the treatment of low birth weight neonates as a cost-effective intervention worldwide.
Introduction
Neonatal sepsis is a worldwide public health problem, with higher incidence in the developing world (Zaidi et al. 2005) . Despite advances in diagnosis and treatment, infections in the neonatal period remain a major cause of death in newborns. Globally, 3.1 millions of neonates die per year, 12 % of them due to sepsis or meningitis (Liu et al. 2012) .
Neonates are at risk to acquire infections, especially preterm and low-birth-weight newborns. In addition to the high morbidity and mortality associated with neonatal sepsis, these patients are at high risk for long-term disabilities, particularly neurodevelopment impairment (Shane and Stoll 2014) . Therefore, several interventions, including intravenous immunoglobulin, glutamine, anti-staphylococcal monoclonal antibodies and granulocyte/granulocyte-macrophage colonystimulating factors have been evaluated for reduction in rates of neonatal sepsis, but have not shown efficacy (Camacho-Gonzalez et al. 2013) . Given the failure of these approaches, lactoferrin (LF) prophylaxis, if effective, could be an important strategy to prevent infections in this period (Shane and Stoll 2013; Camacho-Gonzalez et al. 2013) .
The first trial testing LF for the prevention of lateonset sepsis was performed by Manzoni et al. (2009) in Italy. They found that the incidence of sepsis and death from sepsis were significantly lower in the LF-treated groups compared with the placebo. This study was met with great excitement; however, before LF becomes a standard of care, additional studies should confirm its potential to decrease infections and mortality in premature infants. This article provides an analysis of current and ongoing clinical trials of LF for prevention of neonatal sepsis and gives an update of experimental evidence that supports LF effect against neonatal infections.
Materials and methods
A literature search using Medline, Embase and Lilacs was performed. The following MeSH search headings were used: ''Lactoferrin'', ''Sepsis'', ''Infant, newborn''; these terms were also included as text words and ''talactoferrin'' was added. We also searched the abstract archives of the Pediatric Academic Societies (PAS) meeting, Infectious Diseases Society of America (IDSA) annual meeting, American Academy of Pediatrics (AAP) National Conference and Exhibition and the European Society for Pediatric Infectious Diseases meeting using the search term ''lactoferrin''. In industry-funded trials we searched the sponsor web page for press releases and information about trials. Additionally, we searched for registered clinical trials (randomized and quasi-randomized studies) using the terms ''lactoferrin'' We selected all trial registries, abstracts and information provided by the sponsor or main investigator and discarded duplicated information. We collected data on the trial methodology using the ''PICO'' format (population, intervention, control and outcome), the current status and published results.
Results
In addition to the Manzoni study, we found ten registered clinical trials of LF for prevention of neonatal sepsis worldwide (Table 1) : three in Europe (one in Italy, one in the UK, one in The Netherlands), two in North America (one in US, one in Canada), two in South America (Peru), one in Asia (Turkey), one in Africa (Egypt) and one in Oceania (Australia). The trial from Turkey (Trial # 5 on Table 1 ) has been accepted for publication; four trials (# 1, 2, 4 and 8) have been completed but are not published yet; two studies (# 7 and # 10) are currently recruiting, and two (# 6 and 9) have not started recruitment yet. One trial registry (# 3) has not been updated in more than 2 years and their authors have not answered to our email; therefore, we have considered its status unknown.
Population
The sample size of each trial was between 50 to 2,200 neonates, for a total of 5,713 neonates randomized in eleven trials. The inclusion criteria were based on birth weight, gestational age and/or days of life. Three clinical trials (# 2, 4 and 7) based their eligibility criteria only on the newborn birth weight. Three studies (# 1, 8 and 10) included neonates only All interventions are administered orally according to a maximum gestational age at birth and four (# 3, 5, 6, 9) used both parameters. The maximum birth weight accepted varied from 1,500 to 2,500 g and the maximum birth gestational age varied from 28 to 36 weeks. The majority of studies (# 2, 4, 7, 8, 9 , and 10) enrolled only neonates before 72 h of birth, only 1 trial (# 6) included subjects who were within 7 days of life and 3 trials (# 1, 3, 5) did not specify a maximum age. The most common exclusion criteria was the presence of a congenital underlying condition including chromosomal abnormalities in nine trials, gastrointestinal problems that prevent oral intake in seven trials and family history of milk allergy in five trials. Four trials included all of these exclusion criteria and three included only two.
Intervention
Bovine LF (BLF) was used in nine trials and recombinant human LF (talactoferrin) was used in one (# 2). Five trials (# 2, 4, 6, 7, and 10) gave the intervention according to the birth weight and the dose varied from 150 to 300 mg/kg/day. Three trials (#3, 5, and 8) used a fixed daily dose (from 100 to 200 mg/ day), one used both fixed and weight based dosing (#9) and one (#1) used a dosing of milligram of LF per milliliter of milk (1 mg/100 ml). The duration of treatment was variable, based on weeks of live (4-8 weeks), gestational age (34-36 weeks) or patient discharge from hospital. Two trials did not specify the duration of the intervention.
Control
Four trials (# 1, 3, 6, and 8) did not administered a placebo; that is, the patient continued receiving the standard treatment and feeding (milk or formula without a supplement), without an additional supplementation. Clinical trials from Peru (#4 and 7) used maltodextrin as placebo. Other placebos used were oral saline (# 5) and distilled water (#9). Two trials (# 2 and 10) did not specify what was given as placebo.
Outcome
In all trials the main study outcome was the incidence of late-onset sepsis (LOS), sepsis after 72 h of life, except for trial # 3 which evaluated neurodevelopment as the main outcome. Additional study outcomes were incidence of necrotizing enterocolitis (NEC) (# 2, 5, 6, 8 and 10) and neurodevelopment (# 1, 3 and 7). Sepsis was defined as culture-proven in five trials (# 2, 5, 6, 8 and 9) and clinically-suspected and/or culture-proven in three trials (# 4, 7 and 10). One trial (# 1) did not specify the sepsis definition. NEC was defined as Bell's stage II or greater in three trials (# 5, 8 and 10) and was not specified in two (# 2 and 6). One trial (# 7) evaluated neurodevelopmental outcome using the Mullen Scales; the other trials did not specify the method of neurodevelopmental evaluation.
Published data
The first published trial included 472 very-low-birthweight (VLBW) neonates, who were randomized to three groups: BLF, BLF ? probiotic Lactobacillus rhamnosus (LGG) or placebo. They found a significant reduction of sepsis incidence in the BLF and BLF ?
LGG groups compared with the placebo group (5.9 and 4.6 vs. 17.3 %) (p = 0.002 for BLF vs. control group and p \ 0.001 for BLF ? LGG vs. control group). Death from sepsis also was reduced in both treatment groups compared with placebo (0 and 0.7 vs. 4.8 %, p = 0.008 and p = 0.04, respectively). Extremely-low-birth-weight-neonates (\1,000 g) received the most benefit; neonates with a birth weight of 1,000-1,500 g also had a protective effect, but did not reach statistical significance (Manzoni et al. 2009 ).
Later, Manzoni et al. (2012) performed a secondary analysis of data from the initial multicenter study to determine the effect BLF ± a probiotic on prevention of fungal infections. Invasive fungal infections were significantly decreased in LF groups (0.7 % with BLF and 2.0 % with BLF ? LGG vs. 7.7 % with placebo, p \ 0.05). The incidence of fungal colonization was the same in all three groups; however, the progression rate colonization-infection was significantly lower in the LF groups (3.7 % with BLF and 12 % with BLF ? LGG vs. 41.9 % with placebo, p \ 0.05).
The study performed in Turkey (# 5) has been accepted for publication (personal communication) in the American Journal of Perinatology. This trial included 50 VLBW infants born before 32 weeks gestational age who were assigned either to placebo (saline solution) or to LF (200 mg/day). The LF group developed fewer sepsis episodes than the placebo group (4.4 vs 17.3/1,000 patient-days, p = 0.007).
Preliminary results
The LACUNA trial's (# 8) preliminary results were presented in the 2014 PAS/ASPR Joint Meeting. Seventy-nine patients with \32 weeks of gestational age were included and randomized to LF (100 mg/kg) or placebo. LF was well tolerated and the administration was successfully masked. Seven late-onset sepsis episodes were diagnosed in each arm; nevertheless the study was not powered to detect clinically relevant outcomes.
The talactoferrin clinical trial (# 2) preliminary results have been released in the 2013 PAS Annual Meeting. A total of 120 neonates were enrolled. Bacteremia was seen in 6.7 % of both groups. However, placebo-treated neonates were 2-times (OR: 1.6) more likely to develop an infection (bacteremia, meningitis, pneumonia, urinary tract infection and NEC), although the study was not powered to detect significant reductions in infection. No adverse events related to the intervention were reported.
Our team has completed a multicenter pilot study (# 4) using bovine LF; the preliminary results were presented at the 2012 PAS Annual Meeting and are currently under review for publication. We enrolled 190 neonates with a birth weight of \2,500 g (mean birth weight: 1,591 ± 408 g). BLF (200 mg/kg/day) or placebo (maltodextrine) was administered for 4 weeks and infants were followed until 3 months of postnatal age. The cumulative incidence of late-onset sepsis was lower in the BLF group 12.6 % (12/95) vs. 22.1 % (21/95) in the placebo group, but did not reach statistical significance. In infants B1,500 g the sepsis rate was 20 % (8/40) in the LF group vs. 37.5 % (15/40) in the placebo. There were no adverse events related to the intervention.
We are currently conducting the NEOLACTO trial (# 7) in 3 neonatal units of Lima, Peru, on 414 infants with a birth weight\2,000 g to determine the effect of BLF on neonatal sepsis and neurodevelopment at 24 months of corrected age. We have recruited more than 350 patients currently, and more than 180 sepsis episodes have been evaluated. Since this is an ongoing and blinded trial, we do not have preliminary results yet; nevertheless, the study is being conducted as planned, and no adverse event has been reported related to the investigational product.
Discussion
After the publication of the first clinical trial by Manzoni et al. several ongoing studies are evaluating the same hypothesis in more than 5,000 subjects. Few of these trials have finished and despite their small sample size the preliminary results show a trend towards a positive protective effect of LF on neonatal infections. Larger trials are on the way to confirm the findings of these initial studies.
Before LF could become a standard of care for premature infants, there are several important questions that should be answered. Is LF safe in preterm neonates? Most trials have focused on neonates with a birth weight of \1,500 g; therefore, it's likely that, if LF is proven effective, its use at least initially is going to be limited to VLBW neonates. An important concern regarding LF use in these small premature infants is the potential for adverse events, particularly allergic reactions, since the LF being used is purified from bovine milk. Some researchers have excluded neonates with a family history of coẃ s milk allergy as a safety measure. However, allergy to coẃ s milk protein is due mainly to caseine, alpha-lactalbumin and beta-lactalbumin, but not to LF (Sharma et al. 2001) . Talactoferrin and other recombinant human LFs have the theoretical advantage of reducing this risk, but have the issue of a non-human potentially allergenic glycosylation pattern. So far, more than 400 neonates have received BLF as part of the sepsis trials with no adverse events reported. Additionally, many more infants have received BLF in the past on trials evaluating LF s effect on anemia and fecal flora, with no adverse events (Ochoa et al. 2012) . Nevertheless, long term consequences remains to be assessed; studies performing long term evaluations for neurodevelopment should also look at this safety issue.
Which type of LF should be used in neonates? All, except one trial has used BLF. Bovine LF has [70 % amino acid homology to human LF but has different glycans than human LF. Despite some structural differences, both LFs seem to preserve their functional properties (Baker and Baker 2012) . On the other hand, recombinant human LF is produced in different systems (rice, cows, goats, and fungus-Aspergillus niger var awamori) (Sun et al. 1999 ) and therefore, the glycosylation pattern varies depending on each species source. Currently, there is not enough evidence to support that one type is better or safer than the others (Lingappan et al. 2013) . Bovine LF has the benefit of being significantly less expensive than recombinant human LF, and if effective, is the form most likely to be used for pediatric care.
What is the right LF dose? Dosing regimens are highly heterogeneous between trials. This complicates the comparisons of results and dose selection if LF becomes a standard of care. Manzoni's trial used a fixed dose regimen (100 mg/day) for all infants; however the dosage may be insufficient in larger infants. The ongoing trials (LIFT, NEOLACTO and ELFIN) use a weight based dose ranging from 150 to 200 mg/kg/day. Although this seems to be more appropriate, for real life application (outside the context of a clinical trial) daily dose calculation would require frequent readjustments with growth. Therefore, since LF overdose seems unlikely, simplified dosing regimens should be established based on dosages used in clinical trials (for example: start at 200 mg/day for neonates of \1,000 g and add 100 mg/day for each 500 g over 1,000 g of weight).
If effective, is LF effect on neonatal sepsis pathogen-specific? The main pathogens associated with late-onset sepsis in neonates in developed countries are Gram-positive organisms [coagulase negative Staphylococci (CoNS); Staphylococcus aureus, and Group B Streptococcus (GBS)], which account for 70 % of all episodes (Shane and Stoll 2013) (4). While in developing countries, the main pathogens are Gramnegative bacteria, mainly Klebsiella pneumoniae, Escherichia coli and Pseudomonas, which account for 60 % of all episodes (Zaidi et al. 2005) . Candida species are the third leading cause of late-onset sepsis in prematures and low-birth-weight infants (CamachoGonzalez et al. 2013) . The ongoing clinical trials are being performed in diverse locations providing the opportunity to test LF's effect on different microorganisms. In Manzoni's trial, LF was more effective in fungal and Gram-positive sepsis and was not significantly effective in Gram-negative sepsis, although the study was not powered for this comparison. Additionally, the incidence of fungal sepsis was high compared to other European countries. New trials will test LF effect in settings with higher incidences of Gramnegative sepsis, like developing countries, and with lower incidences of fungal sepsis, like the UK. Some clinical trials are evaluating LF effect on clinicallydefined neonatal sepsis. Although, this is less reliable than culture-proven infections, and will not give information on pathogen-specific protection, these suspected infections accounts for an important percentage of sepsis-like episodes in developing countries (Thaver and Zaidi 2009) .
What is the experimental evidence that supports LF effect against neonatal infections? The protective effect of LF on neonatal sepsis is attributed to its three main functional properties: anti-microbial, antiinflammatory and immunomodulatory. The role of LF in the immunomodulatory pathway and inflammatory response to infections have been extensively studied and reviewed (Vogel 2012; Legrand 2012; Embleton et al. 2013; Lingappan et al. 2013) .
The potential for benefit against specific pathogens varies. Among Gram-positive bacteria, Leitch et al. (1999) demonstrated the anti-staphylococcal activity of LF plus lysozyme against Staphylococcus epidermidis; in vitro studies showed the synergistic effect of recombinant human LF and antimicrobials against coagulase-negative Staphylococci and Candida (Venkatesh and Rong 2008); animal studies revealed the effectiveness of LF in reducing viable Staphylococcus aureus in mice (Nibbering et al. 2001; Artym et al. 2004) . In general, LF binds to the lipoteichoic acid on the surface of Gram-positive organisms, disrupting the bacteria cell membrane and decreasing biofilm formation.
Among Gram-negative bacteria LF causes disruption of bacterial biofilms of specific microorganisms (Ammons and Copie 2013) , such as Pseudomonas (Singh et al. 2002) , Escherichia coli and Klebsiella (Sheffield et al. 2012) ; LF kills antibiotic-resistant Klebsiella pneumoniae in mice (Nibbering et al. 2001) . BLF protects mice from a lethal dose of parenterally administered E. coli (Zagulski et al. 1989) and protects against endotoxin-induced lethal shock in piglets (Lee et al. 1998) . Human LF neutralizes endotoxin (Zhang et al. 1999 ) and protects rats from gut-related E. coli systemic infections (Edde et al. 2001) . LF has been thought to protect against Gramnegative bacteria in a variety of ways. It sequesters iron that is essential for bacterial growth and binds to the lipid A portion of LPS on the cell surface, disrupting the bacterial cell membrane (Ochoa and Cleary 2009) . Additionally, exposure of BLF to pepsin (e.g., in gastric secretions) releases an N terminus peptide fragment (lactoferricin) that is bactericidal in vitro for Gram-positive and Gram-negative bacteria and yeast (Orsi 2004) . These laboratory observations suggest that LF is likely to be beneficial in humans for some infections depending on form of LF, timing, route and size of dose, agent causing infection, additional therapeutic measures, age of patients, and cofactors used in treatment. Additional variables may be important in the analysis, such as the use of carbohydrates (glucose or maltodextrin) as placebo, which may have a prebiotic effect on gut's microbiota and therefore, a possible a protective effect in neonatal sepsis (Watson et al. 2013) .
Conclusion
There are eleven trials evaluating LF effect on neonates. In future years we expect to see a significant amount of data published regarding LF protective effect in late-onset neonatal sepsis. This information will help to define its role in clinical settings and, if proven effective, may profoundly affect the treatment of low birth weight neonates by providing a low cost intervention potentially impacting neonatal morbidity and mortality worldwide.
